102 related articles for article (PubMed ID: 8707769)
21. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
22. [Tumor markers in breast cancer].
Harada Y; Ohuchi N; Ishida T; Ohnuki K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
[TBL] [Abstract][Full Text] [Related]
23. Role of early diagnosis and screening; biomarkers.
Miller AB
Cancer Detect Prev; 1991; 15(1):21-6. PubMed ID: 2044070
[TBL] [Abstract][Full Text] [Related]
24. [Considerations in rational use of tumor markers in breast carcinoma].
Crombach G
Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
26. Serum tumor markers in patients with breast cancer.
Lumachi F; Basso SM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
[TBL] [Abstract][Full Text] [Related]
27. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
28. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
29. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers for breast cancer.
Beenken SW; Bland KI
Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer: the search for new prognostic markers.
Davis AR
Br J Biomed Sci; 1996 Jun; 53(2):157-61. PubMed ID: 8757694
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic and predictive factors in breast cancer].
Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
[TBL] [Abstract][Full Text] [Related]
33. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
Cheung KL; Robertson FR
Minerva Chir; 2003 Jun; 58(3):297-303. PubMed ID: 12955047
[TBL] [Abstract][Full Text] [Related]
34. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
Stearns V; Yamauchi H; Hayes DF
Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086
[TBL] [Abstract][Full Text] [Related]
36. [Application of tumour markers in clinical practice].
Keuren JF; Thomas CM; Bonfrèr JM; Sweep CG; Boonstra JG
Ned Tijdschr Geneeskd; 2009; 153():A617. PubMed ID: 19857306
[TBL] [Abstract][Full Text] [Related]
37. [Utility and specificity of markers of breast cancer].
Hurlimann J
Arch Gynecol Obstet; 1990; 247 Suppl():S86-90. PubMed ID: 2085280
[No Abstract] [Full Text] [Related]
38. Statistical considerations and modeling of clinical utility of tumor markers.
George SL
Hematol Oncol Clin North Am; 1994 Jun; 8(3):457-70. PubMed ID: 8707767
[TBL] [Abstract][Full Text] [Related]
39. [Current technologies of screening for breast cancer].
Rozhkova NI; Bozhenko VK
Vopr Onkol; 2009; 55(4):495-500. PubMed ID: 19947380
[No Abstract] [Full Text] [Related]
40. [Clinical implication of tumor marker expressions suggesting biological characters of malignancies].
Ariyoshi Y; Kuwabara M
Nihon Rinsho; 1996 Jun; 54(6):1568-73. PubMed ID: 8691610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]